Vantia Therapeutics names new head of regulatory affairs

Most recently an independent regulatory affairs consultant, Ms Rachel has also served as senior director and group head of regulatory affairs for the clinical research organization Averion International (previously Hesperion).

Previously, Ms Rachel founded ChapelPharma, a regulatory consultancy that was acquired by Hesperion in 2004.

Jim Phillips, CEO of Vantia Therapeutics, said: “Rachel brings to Vantia years of experience across all regulatory aspects of the global development of new chemical entities from preclinical through to Phase III. She is an excellent addition to our already high-quality management team at Vantia and I look forward to working with her as our clinical and preclinical pipeline continues to mature.”